Add to Calendar
3/13/2019 8:00:00 AM
3/13/2019 10:00:00 AM
The Value of Diversity in Clinical Trials
According to the FDA’s 2017 Drug Snapshot report, 46 novel drugs were approved that year for trials enrolling over 59,000 patients. Of those, 77% were white, 11% were Asian and 7% were Black or African American. There is growing evidence that, whether for environmental or genetic reasons, drugs may have different effects on different populations. The sample bias of these trials can lead to misleading results for all people. The FDA does not mandate drug companies to enroll a greater diversity of patients, but doing so improves the quality on human subjects research and validity of life-saving research on a range of diseases. This forum will discuss the value of designing inclusive trials for a diverse patient population, explore the barriers to attaining diversity in recruitment and provide some examples of how academic medical centers and companies are tacking this problem through innovative and inclusive clinical trial designs, and community engagement and education.
MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139